Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The agilon health, inc. (AGL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. agilon health describes itself as a trusted partner empowering physicians to transition senior patients to a value-based Total Care Model, and its filings offer detail on how this business is structured and governed.
Investors can review current and historical reports such as Form 8-K filings, where agilon health has reported items including quarterly financial results, leadership transitions, amendments to by-laws, and notices related to New York Stock Exchange continued listing standards. These documents give additional context to the company’s announcements about its operations, value-based care arrangements, and corporate governance.
Through its periodic reports referenced in these filings, agilon health discusses topics such as risk factors associated with its value-based care model, relationships with payors and physician partners, and its reliance on medical services as a source of revenue. The filings may also describe compensation and employment arrangements for key executives, as reflected in agreements disclosed in Form 8-K exhibits.
On Stock Titan, users can combine direct access to agilon health’s SEC documents with AI-powered tools that summarize key points and highlight important sections. This can help readers more quickly understand complex disclosures related to financial performance, listing status, executive arrangements, and other matters that affect agilon health’s value-based healthcare business.
agilon health, inc. is implementing a 1-for-25 reverse stock split of its common stock after stockholders approved an amendment to its certificate of incorporation at a special meeting. The proposal passed with 356,574,789 votes for, 6,187,388 against and 365,864 abstentions.
The reverse split is expected to become effective on March 30, 2026, around 5:00 p.m. Eastern Time, with split-adjusted trading on the NYSE beginning March 31, 2026 under the symbol AGL. After the change, every 25 shares will be combined into one share, resulting in approximately 16,605,993 shares outstanding.
The company states the reverse split is intended to increase its share price above $1.00 to meet NYSE minimum bid requirements and potentially improve the marketability and liquidity of the stock. No fractional shares will be issued; holders entitled to fractions will receive cash instead, and equity awards and related instruments will be adjusted proportionally.
agilon health, inc. Chief Legal Officer Denise Zamore reported equity compensation activity tied to performance-based restricted stock units (PSUs). An award granted on April 14, 2023 fully vested on March 9, 2026 after agilon health achieved 42% of predetermined Revenue and Adjusted EBITDA goals over the three-year period from January 1, 2023 through December 31, 2025.
Each vested PSU settled into one share of common stock, resulting in 5,535 shares reported as acquired. In connection with this net settlement, 2,056 shares of common stock were withheld by the company at $0.5999 per share to satisfy income tax withholding and remittance obligations, which the disclosure notes does not represent a sale. Following these transactions, Zamore directly holds 446,604 shares of common stock, a figure that includes restricted stock units.
agilon health Chief Technology Officer Venkatachaliah Girish reported equity transactions tied to a performance-based restricted stock unit award. On March 9, 2026, he acquired 18,448 shares of Common Stock, reflecting the settlement of vested PSUs granted in April 2023 based on three-year revenue and Adjusted EBITDA goals with 42% attainment.
On the same date, 6,477 shares were withheld by agilon health to cover income tax obligations related to the net settlement of these PSUs, and this withholding is explicitly stated not to represent a sale. After these transactions, Girish directly holds 278,607 shares of Common Stock, including restricted stock units.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported equity-related transactions tied to a performance stock award and a small net share increase. On March 9, 2026, he acquired 18,448 shares of common stock, recorded as an open-market purchase.
On the same date, 6,348 shares were withheld by the company to cover income tax obligations from the vesting and settlement of performance-based restricted stock units (PSUs), and this did not represent a sale. The PSUs, granted on April 14, 2023, vested based on revenue and adjusted EBITDA goals with total attainment of 42%. Following these transactions, Shaker directly holds 1,379,774 shares of common stock, and this figure includes restricted stock units.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported an open-market purchase of 500,000 shares of common stock at a weighted average price of $0.6021 per share. After this transaction, he directly owns 1,367,674 shares, a figure that includes restricted stock units.
agilon health, inc. reported weaker results for 2025 but projected a sharp turnaround in 2026. Full-year 2025 revenue slipped to $5.93B from $6.06B, while net loss widened to $391M from $260M as medical margin swung to a $57M loss from $205M of earnings.
Adjusted EBITDA loss nearly doubled to $296M from $154M, and total members on the platform fell 5% to 625,000, reflecting market and payor exits. Despite this, the company guided 2026 revenue to $5.41–$5.58B, medical margin to $300–$350M, and Adjusted EBITDA to between a $15M loss and a $15M profit, implying a breakeven midpoint.
As of December 31, 2025, agilon held $285M in cash, cash equivalents and marketable securities with $35M of total debt, and expects more disciplined contracting, reduced Part D exposure, and $35M+ in operating cost reductions to underpin the 2026 outlook.
agilon health, inc. is calling a virtual special stockholder meeting on March 17, 2026 to vote on a reverse stock split and a possible adjournment of the meeting. Holders of 414,869,759 common shares as of February 17, 2026 may vote.
The main proposal would authorize the board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-25, without changing the total number of authorized shares or the $0.01 par value. This would sharply reduce shares outstanding and raise the share price mathematically, while increasing the pool of authorized but unissued shares.
The company discloses that its stock closed at $0.35 on the record date and that it previously received a NYSE notice for failing the $1.00 minimum bid requirement. The board believes a reverse split may help maintain NYSE listing, but warns there is no assurance the price will rise or remain above $1.00, and that lower share count could reduce liquidity.
Fractional shares would not be issued; instead, aggregated fractional interests would be cashed out. A second proposal would allow adjournment of the special meeting to solicit more proxies if there are not enough votes to approve the reverse split. The board unanimously recommends voting “FOR” both proposals.
agilon health, inc. entered into a Third Amendment to its existing credit agreement, extending the stated maturity of its debt from February 18, 2026 to February 18, 2028. The amendment also revises several key covenants and liquidity requirements.
Management must now maintain at least $50 million in Total Cash at the end of each business day, and certain payments such as dividends to its holding company are conditioned on the Company achieving positive EBITDA for two consecutive trailing four-quarter periods after the amendment date. The amendment reduces revolving credit commitments from $100.0 million to $90.0 million, requires prepayment of term loans when letters of credit are reduced, and mandates cash collateralization of letters of credit at 103% of their amount. Substantially concurrently, agilon health, inc. delivered an unsecured Parent Guaranty of the management entity’s obligations under the amended credit agreement.
agilon health, inc. has called a virtual special stockholder meeting for March 17, 2026 to vote on a reverse stock split and a related adjournment proposal. Stockholders of record as of February 17, 2026 may participate and vote online.
The main proposal would amend the certificate of incorporation to allow a reverse stock split of the common stock at a ratio between one-for-five and one-for-twenty-five, with the exact ratio set later by the board. The split would not reduce authorized shares, so authorized but unissued shares would increase relative to those outstanding.
No fractional shares would be issued; instead, aggregated fractional interests would be paid out in cash. A second proposal would permit adjournment of the meeting to solicit additional proxies if there are not enough votes to approve the reverse split. The board unanimously recommends voting “FOR” both proposals.